The startup develops therapeutics for vascular diseases using a nanoparticle-based technology that facilitates the delivery and expression of therapeutic messenger RNA in endothelial cells. This approach aims to restore endothelial cell function, addressing the dysfunction associated with various vascular conditions.
Funding
$11.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Vascular diseases often stem from endothelial cell dysfunction, hindering the proper functioning of blood vessels. Traditional treatments may not effectively restore endothelial cell function, leading to limited therapeutic outcomes for various vascular conditions. Current mRNA delivery methods often lack the specificity needed to target affected tissues and cells, potentially causing off-target effects and reduced efficacy.
Solution
Pantherna Therapeutics develops mRNA-based therapeutics for vascular diseases, utilizing advanced lipid nanoparticle (LNP) technology to enable cell-selective mRNA delivery and expression. Their platform, based on PTXmRNA™ and PTXΔLNP™ technologies, allows for customized, tissue-targeted mRNA expression by manipulating the surface charge of LNPs to target specific tissues and cell types beyond the liver. This approach facilitates the transient expression of therapeutic proteins, restoring endothelial cell function and addressing the underlying causes of vascular dysfunction. Their lead candidate, PAN004, is an mRNA-LNP formulated to deliver a Tie2 activator selectively to the lung endothelium, promoting intercellular barrier stabilization and preventing vascular permeability in Acute Respiratory Distress Syndrome (ARDS).
Target Audience
Pantherna's primary target audience includes pharmaceutical and biotech companies seeking to partner for the development and clinical translation of novel mRNA therapeutics, as well as patients suffering from Acute Respiratory Distress Syndrome (ARDS) and other vascular diseases.
Features
- PTXmRNA™ platform for tailored UTRs and optional secretion signals to drive potent tissue-specific protein expression
- PTXΔLNP™ technology for customized LNP formulations with surface charge control (anionic, neutral, or cationic)
- Targeted delivery of mRNA to specific tissues and cell types beyond the liver
- LNP002 formulation for selective targeting of the lung endothelium via intravenous administration
- PAN004, an mRNA-LNP candidate for cell-selective delivery of mRNA encoding a Tie2 activator to treat lung edema in ARDS
- Scalable LNP platform for creating optimized non-viral vectors for various tissues and administration routes
- Advanced mRNA modifications for minimized immune activation